Gottlieb to leave FDA
This article was originally published in Pharmaceutical Approvals Monthly
FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb will return to the American Enterprise Institute following his resignation from the agency, effective Jan. 16. Gottlieb will join former FDA/CMS chief Mark McClellan, who joined an AEI/Brookings Institution collaborative center in November after departing CMS in October. Gottlieb is the second senior advisor to von Eschenbach to announce a departure for January: FDA Chief of Staff Patrick Ronan recently said he would resign his post effective Jan. 5...
You may also be interested in...
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
The HHS was responsible for the most major regulations over the last few years of any agency, an OMB report shows.
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.